Biodexa Pharmaceuticals Implements 1-For-10 Reverse ADR Split, New Ratio Now 1 ADR To 100K Ordinary Shares

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces the previously announced ratio change of its American Depositary Receipts ("ADR") from one (1) ADR representing ten thousand (10,000) ordinary shares, to the new ratio of one (1) ADR representing one hundred thousand (100,000) ordinary shares (the "Ratio Change"), became effective at the open of business on July 31, 2025 (U.S. Eastern Time).

 For ADR holders, the Ratio Change will have the same effect as a one-for-ten reverse ADR split. The exchange of one new ADR for every ten previously-held ADRs occurred automatically upon effectiveness, with the previously-held ADRs cancelled and the new ADRs issued by JPMorgan Chase Bank, N.A., the depositary bank for the Company's ADR program.

Total Voting Rights

The number of issued ordinary shares of Biodexa will not be affected by this change. As of the date of this release, the number of issued ordinary shares of the Company is 61,952,308,922. Immediately following the Ratio Change, there were 619,523 ADRs outstanding.